Company Overview - Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers [3] - The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create novel therapies and combination regimens to comprehensively shut down the RAS/MAPK pathway [3] - Erasca has one of the deepest RAS/MAPK pathway-focused pipelines in the industry, supported by a scientific advisory board of leading experts [3] Recent Events - Erasca announced its participation in the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 9:30 am Eastern Time, where management will engage in a fireside chat and one-on-one investor meetings [1] - A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days post-event [2]

Erasca (NASDAQ: ERAS ) is a precision oncology company, which means it focuses on therapies that target very specific cancer-related mutations. In particular, the main pathways it uses are the RAS/MAPK pathways. ERAS has a relatively late-stage pipeline with Naporafenib, whichMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...

Erasca, Inc. (ERAS) has been beaten down lately with too much selling pressure. While the stock has lost 25.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Core Viewpoint - Erasca, Inc. (ERAS) has experienced significant selling pressure, resulting in a 27.2% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - ERAS has an RSI reading of 20.75, suggesting that the heavy selling may be exhausting, indicating a potential rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for ERAS by 1% over the last 30 days, which typically correlates with price appreciation [6] - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a strong potential for a turnaround [7]

Core Viewpoint - Erasca, Inc. (ERAS) is experiencing significant selling pressure, having declined 24.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory and analysts expect better earnings than previously predicted [1] Group 1: Stock Performance and Technical Indicators - The stock's Relative Strength Index (RSI) reading is at 20.63, indicating it is oversold and suggesting a potential reversal in trend [5] - A stock is generally considered oversold when its RSI falls below 30, which helps investors identify entry opportunities for potential rebounds [2][3] Group 2: Earnings Estimates and Analyst Consensus - There is strong agreement among sell-side analysts in raising earnings estimates for ERAS, with a 1% increase in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6] Group 3: Zacks Rank and Investment Potential - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

Core Viewpoint - Erasca, Inc. (ERAS) is experiencing significant selling pressure, with a 22.9% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better earnings than previously predicted [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - ERAS has an RSI reading of 21.15, suggesting that heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for ERAS will improve, with a 1% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6] - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a near-term turnaround [7]

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in ...

Shares of Erasca, Inc. (ERAS) have been struggling lately and have lost 9.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1217027 (S ...

Financial Position - Cash, cash equivalents, and marketable securities totaled $463.3 million as of September 30, 2024, up from $322.0 million as of December 31, 2023, providing a runway into H1 2027[5] - Total assets increased to $528.9 million as of September 30, 2024, compared to $395.3 million as of December 31, 2023[9] - Accumulated deficit reached $(735.4) million as of September 30, 2024, compared to $(606.0) million at the end of 2023[9] Expenses - Research and Development (R&D) expenses increased to $27.6 million for Q3 2024, compared to $25.2 million for Q3 2023, driven by clinical trial and preclinical study costs[5] - General and Administrative (G&A) expenses were $9.6 million for Q3 2024, slightly up from $9.4 million in Q3 2023[6] Net Loss - Net loss for Q3 2024 was $31.2 million, or $(0.11) per share, compared to a net loss of $30.4 million, or $(0.20) per share, in Q3 2023[6] Clinical Trials and Development - The SEACRAFT-2 Phase 3 trial is expected to report randomized dose optimization data in 2025, targeting NRAS-mutant melanoma[4] - IND filings for ERAS-4001 (pan-KRAS inhibitor) are anticipated in Q1 2025, with initial Phase 1 data expected in 2026[4] - IND filing for ERAS-0015 (pan-RAS molecular glue) is expected in H1 2025, with initial Phase 1 data also anticipated in 2026[4] - The company has confirmed potential best-in-class profiles for both ERAS-0015 and ERAS-4001, supporting their development[2]